Accuray introduces new radiation therapy device CyberKnife S7 System

18 June 2020 (Last Updated June 18th, 2020 16:09)

Accuray has launched the CyberKnife S7 System for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments.

Accuray introduces new radiation therapy device CyberKnife S7 System
Accuray’s CyberKnife S7 System is capable of treating cancerous and benign tumours and neurologic disorders. Credit: Accuray Incorporated.

Accuray has launched the CyberKnife S7 System for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments.

This robotic, non-invasive radiation therapy device is capable of treating cancerous and benign tumours throughout the body, and neurologic disorders.

It uses Synchrony motion synchronisation technology that uses artificial intelligence (AI) to adapt radiation delivery in real time to the movement of the patient and tumour throughout the course of treatment.

Movements such as breaths, or coughs, muscles tensing and relaxing, and fluids and gasses displacing internal organs may occur during the treatment and that can impact the location of the tumour target when the radiation beam is delivered.

The robotic design of the system allows the delivery of radiation from a range of unique angles, expanding the possible positions from which radiation beams can be delivered.

It will enable the physician to maximise radiation dose delivered to the tumour and to reduce the dose to surrounding healthy tissues.

Accuray president and CEO Joshua Levine said: “The CyberKnife system has continued to evolve since the first patient was treated more than 25 years ago and it remains the ‘go-to’ device for clinicians who want to confidently deliver precise and accurate stereotactic treatments on a day-in, day-out basis.

“With the introduction of the CyberKnife S7 System, Accuray is continuing its legacy of innovation. We believe this new system will make it easier for Geisinger clinicians to successfully deliver SRS and SBRT and achieve their patient-first treatment objectives, a priority for their team and ours.”